Please enable JavaScript to continue using this application.

Compare $MGNX vs $STRO | Chartloom

Compare

$MGNX vs $STRO

MacroGenics Inc · Sutro Biopharma Inc

MGNX

MacroGenics Inc

STRO

Sutro Biopharma Inc

Compare $MGNX vs $STRO

Comparing MacroGenics Inc and Sutro Biopharma Inc

MGNXMacroGenics Inc

STROSutro Biopharma Inc

MGNXMacroGenics Inc

Market cap

$238M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.39x

Rev growth (TTM)

1.3%

YTD performance

132.3%

52W performance

110.1%

FCF yield

-27.6%

STROSutro Biopharma Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

6.01x

Rev growth (TTM)

-56.3%

YTD performance

30.2%

52W performance

67.2%

FCF yield

-61.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MGNX

STRO

Detailed metrics comparison

MGNX

MacroGenics Inc

STRO

Sutro Biopharma Inc

Market Cap

MGNX$238M

STRO$236M

Enterprise Value

MGNX$302M

STRO$421M

Price

MGNX$3.74

STRO$14.27

P/E Ratio

MGNXN/A

STRON/A

P/S Ratio

MGNX1.42x

STRO5.17x

EV/Sales

MGNX1.80x

STRO9.22x

EV/EBITDA

MGNX5.31x

STRO0.00x

P/B Ratio

MGNX5.32x

STRO5.78x

P/FCF Ratio

MGNXN/A

STRON/A

EV/FCF

MGNX-4.61x

STRO-2.89x

PEG Ratio

MGNXN/A

STRON/A

Forward P/E (NTM)

MGNXN/A

STRON/A

Forward P/S (NTM)

MGNX2.39x

STRO6.01x

Revenue (TTM)

MGNX$168M

STRO$46M

Revenue Growth (YoY)

MGNX1.3%

STRO-56.3%

Forward Rev Growth

MGNX-12.8%

STRO-19.2%

Gross Margin (TTM)

MGNX61.8%

STRO0.0%

Operating Margin (TTM)

MGNX0.0%

STRO0.0%

EBITDA Margin (TTM)

MGNX-20.8%

STRO-275.3%

Net Margin (TTM)

MGNX-8.7%

STRO-395.2%

FCF Margin (TTM)

MGNX-39.1%

STRO-318.6%

Net Income (TTM)

MGNX$-15M

STRO$-181M

FCF (TTM)

MGNX$-66M

STRO$-146M

EPS (TTM)

MGNX-$0.23

STRO-$10.90

ROE (TTM)

MGNX-3127.0%

STRO-22384.0%

ROA (TTM)

MGNX-535.0%

STRO-8812.0%

ROIC (TTM)

MGNX-1017.0%

STRO-22384.0%

Cash

MGNX$114M

STRO$54M

Debt

MGNX$178M

STRO$239M

Net Cash/Debt

MGNX$-64M

STRO$-185M

Current Ratio (TTM)

MGNX2.96x

STRO3.32x

Quick Ratio (TTM)

MGNX2.92x

STRO3.22x

Debt/Equity (TTM)

MGNX4.16x

STRO4.05x

Debt/Assets (TTM)

MGNX0.0%

STRO0.0%

Interest Coverage (TTM)

MGNXN/A

STRON/A

Net Debt/EBITDA (TTM)

MGNX0.00x

STRO0.00x

Beta

MGNX1.25

STRO1.47

52W Performance

MGNX110.1%

STRO67.2%

YTD Performance

MGNX132.3%

STRO30.2%

% from 52W High

MGNX-26.4%

STRO-67.5%

% from 52W Low

MGNX189.9%

STRO99.6%

Asset Turnover (TTM)

MGNX0.61x

STRO0.22x

FCF Yield (TTM)

MGNX-27.6%

STRO-61.6%

Earnings Yield (TTM)

MGNX-6.1%

STRO-76.4%

Dividend Yield (TTM)

MGNXN/A

STRON/A

Rule of 40

MGNX-37.8

STRO-374.9

EV/GP/RG

MGNXN/A

STRON/A

Ticker research

View MGNX research View STRO research

Metric	MGNX MacroGenics Inc	STRO Sutro Biopharma Inc
Market & Valuation
Market Cap	$238M	$236M
Enterprise Value	$302M	$421M
Price	$3.74	$14.27
P/E Ratio	N/A	N/A
P/S Ratio	1.42x	5.17x
EV/Sales	1.80x	9.22x
EV/EBITDA	5.31x	0.00x
P/B Ratio	5.32x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.61x	-2.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.39x	6.01x
Revenue & Growth
Revenue (TTM)	$168M	$46M
Revenue Growth (YoY)	1.3%	-56.3%
Forward Rev Growth	-12.8%	-19.2%
Profitability
Gross Margin (TTM)	61.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-20.8%	-275.3%
Net Margin (TTM)	-8.7%	-395.2%
FCF Margin (TTM)	-39.1%	-318.6%
Net Income (TTM)	$-15M	$-181M
FCF (TTM)	$-66M	$-146M
EPS (TTM)	-$0.23	-$10.90
ROE (TTM)	-3127.0%	-22384.0%
ROA (TTM)	-535.0%	-8812.0%
ROIC (TTM)	-1017.0%	-22384.0%
Financial Health
Cash	$114M	$54M
Debt	$178M	$239M
Net Cash/Debt	$-64M	$-185M
Current Ratio (TTM)	2.96x	3.32x
Quick Ratio (TTM)	2.92x	3.22x
Debt/Equity (TTM)	4.16x	4.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.25	1.47
52W Performance	110.1%	67.2%
YTD Performance	132.3%	30.2%
% from 52W High	-26.4%	-67.5%
% from 52W Low	189.9%	99.6%
Efficiency & Yields
Asset Turnover (TTM)	0.61x	0.22x
FCF Yield (TTM)	-27.6%	-61.6%
Earnings Yield (TTM)	-6.1%	-76.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-37.8	-374.9
EV/GP/RG	N/A	N/A
Ticker research	View MGNX research	View STRO research

Valuation

P/S Ratio

MGNX

1.42x

STRO

5.17x

EV/FCF

MGNX

-4.61x

STRO

-2.89x

Growth & revenue

Revenue Growth TTM

MGNX

1.3%

STRO

-56.3%

Forward Revenue Growth

MGNX

-12.8%

STRO

-19.2%

Profitability & performance

Gross Margin

MGNX

61.8%

STRO

0.0%

ROE

MGNX

-3127.0%

STRO

-22384.0%

FCF Yield %

MGNX

-27.6%

STRO

-61.6%

52-Week Performance

MGNX

110.1%

STRO

67.2%

Detailed metrics comparison

MGNX

MacroGenics Inc

STRO

Sutro Biopharma Inc

Market Cap

MGNX$238M

STRO$236M

Enterprise Value

MGNX$302M

STRO$421M

Price

MGNX$3.74

STRO$14.27

P/E Ratio

MGNXN/A

STRON/A

P/S Ratio

MGNX1.42x

STRO5.17x

EV/Sales

MGNX1.80x

STRO9.22x

EV/EBITDA

MGNX5.31x

STRO0.00x

P/B Ratio

MGNX5.32x

STRO5.78x

P/FCF Ratio

MGNXN/A

STRON/A

EV/FCF

MGNX-4.61x

STRO-2.89x

PEG Ratio

MGNXN/A

STRON/A

Forward P/E (NTM)

MGNXN/A

STRON/A

Forward P/S (NTM)

MGNX2.39x

STRO6.01x

Revenue (TTM)

MGNX$168M

STRO$46M

Revenue Growth (YoY)

MGNX1.3%

STRO-56.3%

Forward Rev Growth

MGNX-12.8%

STRO-19.2%

Gross Margin (TTM)

MGNX61.8%

STRO0.0%

Operating Margin (TTM)

MGNX0.0%

STRO0.0%

EBITDA Margin (TTM)

MGNX-20.8%

STRO-275.3%

Net Margin (TTM)

MGNX-8.7%

STRO-395.2%

FCF Margin (TTM)

MGNX-39.1%

STRO-318.6%

Net Income (TTM)

MGNX$-15M

STRO$-181M

FCF (TTM)

MGNX$-66M

STRO$-146M

EPS (TTM)

MGNX-$0.23

STRO-$10.90

ROE (TTM)

MGNX-3127.0%

STRO-22384.0%

ROA (TTM)

MGNX-535.0%

STRO-8812.0%

ROIC (TTM)

MGNX-1017.0%

STRO-22384.0%

Cash

MGNX$114M

STRO$54M

Debt

MGNX$178M

STRO$239M

Net Cash/Debt

MGNX$-64M

STRO$-185M

Current Ratio (TTM)

MGNX2.96x

STRO3.32x

Quick Ratio (TTM)

MGNX2.92x

STRO3.22x

Debt/Equity (TTM)

MGNX4.16x

STRO4.05x

Debt/Assets (TTM)

MGNX0.0%

STRO0.0%

Interest Coverage (TTM)

MGNXN/A

STRON/A

Net Debt/EBITDA (TTM)

MGNX0.00x

STRO0.00x

Beta

MGNX1.25

STRO1.47

52W Performance

MGNX110.1%

STRO67.2%

YTD Performance

MGNX132.3%

STRO30.2%

% from 52W High

MGNX-26.4%

STRO-67.5%

% from 52W Low

MGNX189.9%

STRO99.6%

Asset Turnover (TTM)

MGNX0.61x

STRO0.22x

FCF Yield (TTM)

MGNX-27.6%

STRO-61.6%

Earnings Yield (TTM)

MGNX-6.1%

STRO-76.4%

Dividend Yield (TTM)

MGNXN/A

STRON/A

Rule of 40

MGNX-37.8

STRO-374.9

EV/GP/RG

MGNXN/A

STRON/A

Ticker research

View MGNX research View STRO research

Metric	MGNX MacroGenics Inc	STRO Sutro Biopharma Inc
Market & Valuation
Market Cap	$238M	$236M
Enterprise Value	$302M	$421M
Price	$3.74	$14.27
P/E Ratio	N/A	N/A
P/S Ratio	1.42x	5.17x
EV/Sales	1.80x	9.22x
EV/EBITDA	5.31x	0.00x
P/B Ratio	5.32x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.61x	-2.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	2.39x	6.01x
Revenue & Growth
Revenue (TTM)	$168M	$46M
Revenue Growth (YoY)	1.3%	-56.3%
Forward Rev Growth	-12.8%	-19.2%
Profitability
Gross Margin (TTM)	61.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-20.8%	-275.3%
Net Margin (TTM)	-8.7%	-395.2%
FCF Margin (TTM)	-39.1%	-318.6%
Net Income (TTM)	$-15M	$-181M
FCF (TTM)	$-66M	$-146M
EPS (TTM)	-$0.23	-$10.90
ROE (TTM)	-3127.0%	-22384.0%
ROA (TTM)	-535.0%	-8812.0%
ROIC (TTM)	-1017.0%	-22384.0%
Financial Health
Cash	$114M	$54M
Debt	$178M	$239M
Net Cash/Debt	$-64M	$-185M
Current Ratio (TTM)	2.96x	3.32x
Quick Ratio (TTM)	2.92x	3.22x
Debt/Equity (TTM)	4.16x	4.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.25	1.47
52W Performance	110.1%	67.2%
YTD Performance	132.3%	30.2%
% from 52W High	-26.4%	-67.5%
% from 52W Low	189.9%	99.6%
Efficiency & Yields
Asset Turnover (TTM)	0.61x	0.22x
FCF Yield (TTM)	-27.6%	-61.6%
Earnings Yield (TTM)	-6.1%	-76.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-37.8	-374.9
EV/GP/RG	N/A	N/A
Ticker research	View MGNX research	View STRO research